【発明の名称】進行性免疫抑制症患者の評価と治療

Title:

【発明の名称】進行性免疫抑制症患者の評価と治療

Document Type and Number:

Japanese Patent JPH08504170

Kind Code:

A

Abstract:

A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF- kappa B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.

More Like This:

WO/2006/010938	MUTATIONS IN ERB2 ASSOCIATED WITH CANCEROUS PHENOTYPES
WO/1995/029983	PROCESS FOR EVALUATING FERTILITY OF SPERMATOZOA SAMPLES
WO/2003/076623	Cdc7-ASK KINASE COMPLEX, SUBSTRATE OF THE KINASE COMPLEX, ANTIBODY SPECIFIC TO THE SUBSTRATE, AND METHOD OF SCREENING COMPOUND CAPABLE OF INHIBITING Cdc7-ASK KINASE USING THE SAME

Inventors:

Ochoa, August Sea
Mizoguchi Hiromoto
Oshear, John Jay
Longo, Dan El
Roovler, Cynthia M
Gauche, Paris
Young, Howard A

Application Number:

JP51761293A

Publication Date:

May 07, 1996

Filing Date:

April 06, 1993

Export Citation:

Click for automatic bibliography generation Help

Assignee:

OCHOA AUGUSTO C (US)
MIZOGUCHI HIROMOTO (US)
SHEA JOHN J O (US)
LONGO DAN L (US)
LOEFFLER CYNTHIA T (US)
GHOSH PARITOSH (US)
YOUNG HOWARD A (US)

International Classes:

G01N33/50; A61K31/70; A61K31/7088; A61K35/12; A61K35/16; A61K35/24; A61K35/26; A61K35/28; A61K35/30; A61K38/00; A61K38/20; A61K39/00; A61K39/395; A61K45/00; A61K48/00; A61K49/00; A61P5/14; A61P17/00; A61P29/00; A61P31/04; A61P31/08; A61P31/18; A61P31/20; A61P33/06; A61P33/12; A61P35/00; A61P37/00; A61P37/02; A61P37/04; A61P37/06; A61P43/00; C07H21/04; C07K14/47; C07K16/18; C12N5/10; C12N15/09; C12Q1/02; C12Q1/48; C12Q1/68; G01N33/15; G01N33/53; G01N33/574; G01N33/577; (IPC1-7): C07K14/47; A61K31/70; A61K35/12; A61K35/16; A61K38/00; A61K39/00; A61K48/00; A61K49/00; C07H21/04; C07K16/18; C12N5/10; C12N15/09; C12Q1/02; C12Q1/48; C12Q1/68

Attorney, Agent or Firm:

Nao Okuyama (3 others)

Previous Patent: 脂質−Ａ類縁体：治療用抗体を誘発するためのならびに抗腫瘍および抗ウ�...

Next Patent: セレクチン結合のペプチド阻害剤